This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Huntington's disease (HD)	Dynamin 1-like (DNM1L; DRP1)	<i>In vitro</i> and mouse studies suggest that decreasing DRP1 activity could help treat HD. In human neurons expressing a mutant form of the huntingtin (HTT) protein, expression of a DRP1 variant with less enzymatic activity led to lower mitochondrial fragmentation and less cell death than expression of wild-type DRP1. Next steps include testing DRP1 inhibition in animal models of HD.	Patent and licensing status unavailable	Song, W. <i>et al. Nat. Med.</i> ; published online Feb. 20, 2011; doi:10.1038/nm.2313 Contact: Ella Bossy-Wetzel, University of Central Florida, Orlando, Fla. e-mail: ebossywe@mail.ucf.edu
<i>SciBX</i> 4(10); doi:10.1038/scibx.2011.288 Published online March 10, 2011				